Collaborative Research: Cell-free glycoprotein synthesis technology for point-of-care vacc — NSF Award to Stanford University (CA,
Drug-resistant bacteria are a growing threat to human health. By the year 2050, up to 10 million lives per year could be at risk. New strategies will be needed to counter this threat. Vaccines have been developed to safely and effectively prevent dangerous bacterial infections. This project seeks to address current lim
| Award title | Collaborative Research: Cell-free glycoprotein synthesis technology for point-of-care vacc |
|---|---|
| Award ID | 2341123 |
| Awardee | Stanford University |
| City | STANFORD |
| State | CA |
| Amount obligated | $219,067 |
| Principal investigator | Michael Jewett |
| Program | Cellular & Biochem Engineering |
| Start date | 03/01/2023 |
| Abstract | Drug-resistant bacteria are a growing threat to human health. By the year 2050, up to 10 million lives per year could be at risk. New strategies will be needed to counter this threat. Vaccines have been developed to safely and effectively prevent dangerous bacterial infections. This project seeks to address current limitations in vaccine production. Cell-free technology for vaccine production that can be easily scaled up will be developed. This could lead to portable, on-demand vaccine developme |
| Source | NSF Awards |
$799/mo
Try NSFGrants →